Bijal Dave, MD
Family Medicine · Hackettstown, NJNPI 1770733321
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 63.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2022 at $14,948 and has fallen 87.2% since, to $1,913 in 2025. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 741 payments — averaging $33.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$16K
- Boehringer Ingelheim$1K
- Boston Scientific$979
- Amgen$839
- AstraZeneca$804
- AbbVie$713
- plus $4K from 38 others
What the payments were for
- Consulting fees$3,06012%
- Speaking & faculty fees$9,80939%
- Food & beverage$12,20249%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$10,182
- JARDIANCE$361
- Watchman$335
- WATCHMAN FLX$243
- WATCHMAN Access System$121
- Wegovy$112
- Saxenda$100
How this compares
$25,078 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 231 | $267,884 |
| JardianceEmpagliflozin | 168 | $195,464 |
| MounjaroTirzepatide | 159 | $181,889 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $30,913 |
| EliquisApixaban | 29 | $29,719 |
| TrulicityDulaglutide | 13 | $26,281 |
| JanuviaSitagliptin Phosphate | 33 | $25,524 |
| MyrbetriqMirabegron | 18 | $16,124 |
| RybelsusSemaglutide | 15 | $14,564 |
| FarxigaDapagliflozin Propanediol | 13 | $14,162 |
| Repatha SureclickEvolocumab | 11 | $13,575 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $11,949 |
| TradjentaLinagliptin | 11 | $11,378 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 128 | $6,121 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 26 | $5,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $15,973 | $282,448246 claims |
| Lilly USA, LLCMounjaro, Trulicity | $467 | $208,170172 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,431 | $206,842179 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $804 | $45,07454 claims |
| PfizerEliquis | $403 | $29,71929 claims |
| MerckJanuvia | $228 | $25,52433 claims |
| GSKAnoro Ellipta, Breo Ellipta | $197 | $16,54023 claims |
| Astellas Pharma US IncMyrbetriq | $157 | $16,12418 claims |
| AbbVieSynthroid | $713 | $2,36339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Hackettstown
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.